Wall Street brokerages forecast that Leap Therapeutics Inc (NASDAQ:LPTX) will report ($0.32) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Leap Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.28) and the lowest estimate coming in at ($0.35). Leap Therapeutics posted earnings per share of ($0.50) in the same quarter last year, which would suggest a positive year-over-year growth rate of 36%. The firm is expected to issue its next earnings report on Monday, April 6th.

On average, analysts expect that Leap Therapeutics will report full-year earnings of ($1.42) per share for the current year, with EPS estimates ranging from ($1.50) to ($1.38). For the next financial year, analysts forecast that the firm will post earnings of ($0.99) per share, with EPS estimates ranging from ($1.71) to ($0.67). Zacks’ EPS calculations are a mean average based on a survey of research firms that that provide coverage for Leap Therapeutics.

Leap Therapeutics (NASDAQ:LPTX) last posted its quarterly earnings data on Thursday, November 14th. The company reported ($0.33) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.33).

A number of analysts have recently weighed in on LPTX shares. ValuEngine downgraded shares of Leap Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 1st. Zacks Investment Research cut shares of Leap Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, January 16th. HC Wainwright reaffirmed a “buy” rating and issued a $3.25 price target on shares of Leap Therapeutics in a report on Friday, November 15th. Robert W. Baird initiated coverage on shares of Leap Therapeutics in a research note on Monday. They set an “outperform” rating and a $6.00 price objective on the stock. Finally, Raymond James raised shares of Leap Therapeutics from a “market perform” rating to an “outperform” rating and set a $2.50 price objective for the company in a report on Wednesday, January 8th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $3.25.

Shares of LPTX traded up $0.14 during trading on Friday, reaching $2.15. The company’s stock had a trading volume of 269,982 shares, compared to its average volume of 1,234,241. The company has a market cap of $49.36 million, a price-to-earnings ratio of -2.01 and a beta of 2.24. The company has a quick ratio of 1.39, a current ratio of 1.39 and a debt-to-equity ratio of 0.12. The company has a fifty day moving average of $1.71 and a two-hundred day moving average of $1.38. Leap Therapeutics has a twelve month low of $0.57 and a twelve month high of $2.97.

Institutional investors have recently made changes to their positions in the stock. Virtu Financial LLC acquired a new stake in Leap Therapeutics during the third quarter valued at approximately $28,000. Bank of New York Mellon Corp bought a new position in Leap Therapeutics during the 2nd quarter worth approximately $42,000. BlackRock Inc. lifted its holdings in Leap Therapeutics by 40.0% during the 2nd quarter. BlackRock Inc. now owns 34,233 shares of the company’s stock worth $61,000 after buying an additional 9,782 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Leap Therapeutics by 183.4% in the 2nd quarter. Vanguard Group Inc. now owns 555,195 shares of the company’s stock worth $994,000 after acquiring an additional 359,320 shares in the last quarter. Finally, FMR LLC grew its position in shares of Leap Therapeutics by 63.3% in the 1st quarter. FMR LLC now owns 1,563,124 shares of the company’s stock worth $2,923,000 after acquiring an additional 606,000 shares in the last quarter. 15.61% of the stock is owned by hedge funds and other institutional investors.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer.

Featured Story: If I purchase shares through a brokerage account, am I the holder of record?

Get a free copy of the Zacks research report on Leap Therapeutics (LPTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.